Does plasmid-based beta-lactam resistance increase E. coli infections: Modelling addition and replacement mechanisms

PLoS Comput Biol. 2022 Mar 14;18(3):e1009875. doi: 10.1371/journal.pcbi.1009875. eCollection 2022 Mar.

Abstract

Infections caused by antibiotic-resistant bacteria have become more prevalent during past decades. Yet, it is unknown whether such infections occur in addition to infections with antibiotic-susceptible bacteria, thereby increasing the incidence of infections, or whether they replace such infections, leaving the total incidence unaffected. Observational longitudinal studies cannot separate both mechanisms. Using plasmid-based beta-lactam resistant E. coli as example we applied mathematical modelling to investigate whether seven biological mechanisms would lead to replacement or addition of infections. We use a mathematical neutral null model of individuals colonized with susceptible and/or resistant E. coli, with two mechanisms implying a fitness cost, i.e., increased clearance and decreased growth of resistant strains, and five mechanisms benefitting resistance, i.e., 1) increased virulence, 2) increased transmission, 3) decreased clearance of resistant strains, 4) increased rate of horizontal plasmid transfer, and 5) increased clearance of susceptible E. coli due to antibiotics. Each mechanism is modelled separately to estimate addition to or replacement of antibiotic-susceptible infections. Fitness costs cause resistant strains to die out if other strain characteristics are maintained equal. Under the assumptions tested, increased virulence is the only mechanism that increases the total number of infections. Other benefits of resistance lead to replacement of susceptible infections without changing the total number of infections. As there is no biological evidence that plasmid-based beta-lactam resistance increases virulence, these findings suggest that the burden of disease is determined by attributable effects of resistance rather than by an increase in the number of infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Escherichia coli Infections* / epidemiology
  • Escherichia coli Infections* / microbiology
  • Escherichia coli* / genetics
  • Humans
  • Plasmids / genetics
  • beta-Lactam Resistance / genetics

Substances

  • Anti-Bacterial Agents

Grants and funding

This research was part of the Risk and Disease burden of Antimicrobial Resistance (RaDAR) project, which was funded through the One Health European Joint Programme by the EU’s Horizon-2020 Research and Innovation Programme (grant 773830) (https://ec.europa.eu/info/research-and-innovation_en).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. M.C.J.B. and N.G.G. were funded through this grant.